1 October 2020 - Shionogi's Rizmoic (naldemedine) will be available on the National Health Service to treat patients with opioid-induced constipation who have already tried a laxative.

The drug is an oral peripherally acting mu-opioid receptor antagonist (PAMORA), approved in Europe on the back of evidence showing that is increases the frequency of bowel movements compared with no treatment and other PAMORAs.

In two other studies, involving 1,095 patients taking opioids for chronic pain caused by a condition other than cancer, 50% of patients taking Rizmoic for 12 weeks achieved the desired outcome, compared with 34% of patients taking placebo.

Read Pharma Times article